The off-switch

Melanocortin antagonists: the drugs and peptides that switch the system off

A melanocortin antagonist blocks a receptor so α-MSH or ACTH cannot activate it — the map of natural brakes, research tools, and clinical antagonists for cachexia and adrenal disease.

By melanocortin.com editorialLast updated 2026

Every agonist story has a mirror — the same receptors, held shut, where too much signal is the disease.

Nearly every headline melanocortin drug switches a receptor on. The quieter half of the field switches one off. Antagonists matter because several diseases are driven by too much melanocortin tone — appetite jammed shut in cachexia, adrenal androgens roaring under excess ACTH — and because the body already runs on natural brakes. This is the map of them: the endogenous blockers, the research tools that proved the biology, and the clinical antagonists now in trials.[1]

What "antagonist" means here

An antagonist binds a receptor and blocks it, so the natural signal cannot get through. A neutral antagonist occupies the site without changing the receptor’s baseline activity; an inverse agonist goes further and suppresses constitutive signalling. At melanocortin receptors the distinction is real: Pfizer’s PF-07258669 was designed as a neutral MC4R antagonist, while the body’s own AgRP behaves as an inverse agonist at MC4R.[3][5]The counterpart page — the drugs that turn the system on — is melanocortin agonists.

The body makes its own brakes

Two peptides, from genes outside POMC, are the system’s natural antagonists:

  • AgRP — expressed in the arcuate nucleus; blocks MC3R and MC4R and drives hunger. It is the endogenous reason an MC4R antagonist can restore appetite.[3]
  • ASIP (agouti signalling protein) — the pigment off-switch; blocks MC1R and tips melanin production from dark eumelanin toward lighter pheomelanin.

Together they are the proof that antagonism is not a drug-company invention — it is how the system is wired.

The classic research tool: SHU9119

SHU9119 is the reference melanocortin antagonist: a cyclic peptide from the same Arizona chemistry that produced Melanotan II, flipped into a blocker by a bulky D-Nal substitution at position 7.[2] It antagonises MC3R and MC4R, is a partial agonist at MC5R, and is an agonist at MC1R — which is why it can silence the appetite receptor while leaving the pigment receptor on. Injected into the brain it makes animals eat. That experiment is the foundation under every later MC4R-antagonist drug.

Clinical antagonists — two diseases of excess

The therapeutic antagonists cluster around two problems where the system is over-driven:

AntagonistTargetStatusDeveloped for
TCMCB07 (mifomelatide)MC3R/MC4RPhase 2Cancer cachexia / wasting
PF-07258669MC4R (neutral)Discontinued (Phase 1)Appetite loss / malnutrition
Atumelnant (CRN04894)MC2RPhase 3CAH · ACTH-dependent Cushing’s
SHU9119MC3R/MC4R (tool)Research onlyMaps the appetite brake

Cachexia — MC4R in reverse

In cachexia, inflammatory signals over-activate central MC4R and jam the appetite rheostat toward “stop eating and burn.” An MC4R antagonist lifts that brake. TCMCB07 (mifomelatide) is the peptide in Phase 2 for cancer cachexia — effectively a drug version of AgRP’s job.[4] PF-07258669 was Pfizer’s oral small-molecule attempt at the same target: potent, selective, structure-designed, efficacious in aged-rat cachexia, then discontinued in Phase 1 for a business decision rather than a safety concern.[5]

Adrenal disease — the first MC2R blocker

Atumelnant (CRN04894) is the clearest clinical example of blocking a melanocortin receptor as a therapeutic strategy. It is an oral MC2R antagonist aimed at congenital adrenal hyperplasia and ACTH-dependent Cushing’s — conditions driven by too much ACTH signalling at the adrenal. In open-label Phase 2 it cut adrenal androgen precursors substantially and has moved into pivotal Phase 3 work.[6] The drug has its own page; the receptor mechanism stays on MC2R, and the status stays in the pipeline table. It is also the antagonist that balances the site’s agonist-heavy framing: melanocortin medicine is not only “turn it on.”

The honest bottom line

Antagonists are the smaller, earlier half of melanocortin pharmacology — and the half that makes the system bidirectional. Natural brakes (AgRP, ASIP), a definitive research tool (SHU9119), cachexia programmes that run MC4R backwards, and an MC2R blocker in Phase 3 for adrenal disease: that is the off-switch ledger. Read it next to the agonists hub, and track status on the pipeline and therapeutics pages.

Education, not a protocol

This page maps the melanocortin antagonist landscape. It does not provide dosing, sourcing, or usage instructions, and it is not medical advice or an endorsement of unapproved use. See the editorial standards.

Common questions

What is a melanocortin antagonist?

A melanocortin antagonist binds one or more of the five melanocortin receptors and blocks them so the natural activator (α-MSH or ACTH) cannot switch the receptor on. Some go further: AgRP is also an inverse agonist at MC4R, pushing the receptor below its resting activity. Antagonists are the mirror image of agonists such as setmelanotide or afamelanotide.

Why block a melanocortin receptor instead of activating it?

Because some diseases are driven by too much melanocortin tone, not too little. Over-active central MC4R signalling collapses appetite in cachexia; excess ACTH signalling at adrenal MC2R drives androgen overproduction in congenital adrenal hyperplasia and cortisol excess in ACTH-dependent Cushing’s. Blocking the receptor treats the direction of the problem.

What are the body’s own melanocortin antagonists?

Two peptides, made from their own genes rather than from POMC: agouti-related peptide (AgRP), which blocks MC3R and MC4R to drive hunger, and agouti signalling protein (ASIP), which blocks MC1R to switch pigment from dark eumelanin toward lighter pheomelanin.

Are any melanocortin antagonists FDA-approved?

Not yet as purpose-built melanocortin antagonists. The clinical antagonists — TCMCB07 for cachexia, atumelnant for CAH/Cushing’s, and the discontinued PF-07258669 — remain investigational. SHU9119 is a research tool, not a medicine.

How is an antagonist different from an inverse agonist?

A neutral antagonist occupies the receptor and blocks the agonist without changing the receptor’s baseline activity. An inverse agonist actively suppresses constitutive (agonist-independent) signalling. AgRP behaves as an inverse agonist at MC4R; PF-07258669 was designed as a neutral antagonist.

References

  1. 1.Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 27(7):736–49. 2006. link ↗
  2. 2.Hruby VJ, Lu D, Sharma SD, et al. Cyclic lactam α-melanotropin analogues with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. 38(18):3454–61 — the SHU9119 design paper. 1995. link ↗
  3. 3.Ollmann MM, Wilson BD, Yang YK, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 278(5335):135–8. 1997. link ↗
  4. 4.Zhu X, et al. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexia. J Clin Invest. 130(9):4921–34. 2020. link ↗
  5. 5.Garnsey MR, Smith AC, et al. Discovery of the potent and selective MC4R antagonist PF-07258669 for the potential treatment of appetite loss. J Med Chem. 66(5):3195–3211. 2023. link ↗
  6. 6.Srirangalingam U, Bruera D, Ayala A, et al. Once-daily oral atumelnant (CRN04894) induces rapid, substantial, and sustained reductions of androstenedione and 17-hydroxyprogesterone in adults with classical congenital adrenal hyperplasia: interim results from a 12-week, phase 2, open-label study. J Endocr Soc. 9(Suppl 1):bvaf149.272 (OR07-06) — Phase 2 CAH readout for the first clinical MC2R antagonist. 2025. link ↗